Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$14.61 USD
+0.20 (1.38%)
Updated Aug 23, 2024 03:49 PM ET
After-Market: $14.40 -0.21 (-1.44%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Assembly Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 130 | 92 | 147 | 216 | 274 |
Receivables | 0 | 1 | 0 | 1 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 7 | 7 | 5 |
Total Current Assets | 134 | 97 | 154 | 224 | 283 |
Net Property & Equipment | 0 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 28 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 42 | 42 |
Deposits & Other Assets | 0 | 1 | 2 | 6 | 2 |
Total Assets | 137 | 102 | 191 | 283 | 340 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 2 | 3 | 5 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 10 | 10 | 16 | 13 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 31 | 0 | 0 | 0 | 6 |
Total Current Liabilities | 39 | 16 | 16 | 24 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 55 | 3 | 3 | 12 | 33 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 96 | 19 | 22 | 43 | 67 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 827 | 808 | 801 | 742 | 713 |
Retained Earnings | -786 | -725 | -631 | -502 | -439 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 41 | 83 | 169 | 241 | 273 |
Total Liabilities & Shareholder's Equity | 137 | 102 | 191 | 283 | 340 |
Total Common Equity | 41 | 83 | 169 | 241 | 273 |
Shares Outstanding | 5.40 | 4.00 | 3.90 | 2.70 | 2.10 |
Book Value Per Share | 7.61 | 20.67 | 43.32 | 89.10 | 130.10 |
Fiscal Year End for Assembly Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 109 | 113 | 130 | 46 | 60 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 4 | 4 | 3 | 4 |
Total Current Assets | 113 | 117 | 134 | 50 | 64 |
Net Property & Equipment | 0 | 0 | 0 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 1 | 0 |
Total Assets | 115 | 120 | 137 | 52 | 67 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 0 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 4 | 7 | 6 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 33 | 33 | 31 | 0 | 0 |
Total Current Liabilities | 41 | 39 | 39 | 7 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 39 | 48 | 55 | 3 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 81 | 87 | 96 | 10 | 12 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 841 | 828 | 827 | 817 | 816 |
Retained Earnings | -806 | -795 | -786 | -775 | -760 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 35 | 33 | 41 | 42 | 55 |
Total Liabilities & Shareholder's Equity | 115 | 120 | 137 | 52 | 67 |
Total Common Equity | 35 | 33 | 41 | 42 | 55 |
Shares Outstanding | 5.50 | 5.40 | 5.40 | 4.30 | 4.30 |
Book Value Per Share | 6.31 | 6.04 | 7.61 | 9.70 | 12.78 |